[A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb
A
A
Constans
J
J
Mahon
F-X
FX
D001549:Benzamides; D002478:Cells, Cultured / Q000187:drug effects; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000187:drug effects; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D012867:Skin / Q000187:drug effects
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor